Scientists identify protein that spurs formation of Alzheimer’s plaques

Rockefeller researchers report that the cancer drug Gleevec reduces Alzheimer’s plaques in a mouse model of the disease by binding to a molecule called gamma-secretase activating protein, or GSAP. By knocking out the gene that produces GSAP, the researchers reduced the primary component of senile plaques. They say that the development of compounds that work like Gleevec and target GSAP could revolutionize the treatment of this disease.

Read the whole article on The Rockefeller University

More from The Rockefeller University